The pilot involved several CDER employees working together with OEA employees to respond to drug related inquiries posted on FDA’s Facebook page.
In 2014, The FDA’s Office of External Affairs (OEA) and Center for Drug Evaluation and Research (CDER) began a 90-day pilot program to improve consumer engagement by enhancing its social media responses, specifically to drug related inquiries more quickly and proactively. The pilot involved several CDER employees working together with OEA employees to respond to drug related inquiries posted on FDA’s Facebook page. The pilot was successful and as a result has become a permanent program.
Other highlights from the social media update are the dashboards offered-OEA Dashboard within the OC Administrative Offices Dashboard. Also noted in the dashboards is the delay of an implementation for an FDA-wide social media policy, targeted now for end of May 2016.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
2 Commerce Drive
Cranbury, NJ 08512